IL3 Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma line, engineered to disrupt the IL3 gene encoding interleukin-3 (IL-3). The polyclonal format provides a mixed population of edited cells, enabling functional loss-of-function studies while capturing population-level responses. This gene-edited product allows researchers to interrogate IL-3-mediated signaling independent of clonal variation and is supplied as a ready-to-use proliferative cell culture for immediate experimental deployment.
The parental A2780 cell line is a well-characterized adherent epithelial model isolated from an untreated ovarian carcinoma patient. These cells are tumorigenic and widely employed as a human ovarian cancer model, offering a platform for investigating oncogenic signaling, drug response, and tumor biology. The A2780 line retains key features of epithelial ovarian carcinoma, making it suitable for studies of tumor?Cimmune interactions and cytokine networks within the tumor microenvironment.
IL-3 is a cytokine that stimulates myeloid progenitor cell proliferation and promotes eosinophil, basophil, and mast cell survival. It signals through a heterodimeric receptor comprising IL3RA and CSF2RB, which activates JAK2 kinase. JAK2 phosphorylates STAT5 and STAT3 transcription factors and triggers the MAPK/ERK and PI3K-AKT cascades. Downstream effectors include Bcl-2 family proteins, cyclins, and c-Myc, collectively driving proliferation and survival. Upstream, IL-3 expression is regulated by NFAT and AP-1 in activated T cells, mast cells, and eosinophils, often following allergen exposure or T-cell receptor activation.
Ectopic IL-3 expression in the non-hematopoietic A2780 context provides a unique system to dissect signaling outside immune cells. Since A2780 cells are not IL-3-dependent, knockout enables study of autocrine/paracrine effects on proliferation, survival, migration, and immune recruitment in co-culture, helping analyze tumor microenvironment dynamics and potential roles in immune evasion or therapy resistance.
Applications include functional IL-3 studies in non-hematopoietic tumors, tumor-immune crosstalk, and gene editing specificity. Suitable assays: western blotting, RT-qPCR, flow cytometry, proliferation, viability, migration, and ELISA. Contact Ascent Research for details.
